Durect (NASDAQ: DRRX)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-01 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.050 | ||||||
REV | 3.840M | 2.076M | -1.764M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Durect (NASDAQ: DRRX) through any online brokerage.
Other companies in Durect’s space includes: Satsuma Pharmaceuticals (NASDAQ:STSA), SCYNEXIS (NASDAQ:SCYX), Rani Therapeutics Hldgs (NASDAQ:RANI), Anebulo Pharmaceuticals (NASDAQ:ANEB) and Endo International (NASDAQ:ENDP).
The latest price target for Durect (NASDAQ: DRRX) was reported by HC Wainwright & Co. on Wednesday, May 5, 2021. The analyst firm set a price target for 6.00 expecting DRRX to rise to within 12 months (a possible 669.23% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Durect (NASDAQ: DRRX) is $0.78 last updated August 12, 2022, 8:00 PM UTC.
There are no upcoming dividends for Durect.
Durect’s Q3 earnings are confirmed for Tuesday, November 1, 2022.
There is no upcoming split for Durect.
Durect is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.